True Freedom Investing LLC Makes New $3.80 Million Investment in IQVIA Holdings Inc. $IQV

True Freedom Investing LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 22,297 shares of the medical research company’s stock, valued at approximately $3,803,000.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. BlackRock Inc. bought a new stake in IQVIA in the second quarter valued at approximately $2,811,292,000. Geode Capital Management LLC raised its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners boosted its position in shares of IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after purchasing an additional 530,672 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after buying an additional 528,753 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE IQV opened at $260.17 on Friday. The company has a fifty day moving average price of $213.32 and a 200 day moving average price of $187.52. The firm has a market cap of $42.82 billion, a PE ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $260.40.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Transactions at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider W Richard Staub sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 in the last 90 days. 1.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Robert W. Baird boosted their price objective on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.